© 2021 MJH Life Sciences and Patient Care Online. All rights reserved.
© 2021 MJH Life Sciences™ and Patient Care Online. All rights reserved.
July 26, 2019
One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.
June 25, 2019
ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.
ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials. Highlights, here.
June 17, 2019
ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.
September 13, 2018
Fremanezumab shown to be effective in treating acute and episodic migraine, according to a new presentation at PAINWeek 2018.
September 11, 2018
News from PAINWeek 2018: "Tapering [opioids] is not detoxification," was one among many cautions and recommendations offered during several presentations in Las Vegas, Sept 4-8.
News from PAINWeek 2018: Lofexidine is found particularly suited to mitigate symptoms of rapid opioid withdrawal given its agonist activity at the 5-HT-1A serotonin receptor.
September 10, 2018
News from PAINWeek 2018: Electroceuticals could replace opioids in the treatment of chronic pain.
July 03, 2018
Severe hypoglycemia is more prevalent than previously believed and also significantly underreported. Details from 3 studies at ADA 2018.
From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.